Diagnostic values of FibroScan and FibroTouch for liver fibrosis: a comparative analysis

Wu Na; Zhang MingYuan; Wu RuiHong; Zhang YingWen; Jin JingLan; Zhu YingQiao; Niu JunQi

doi:10.3969/j.issn.1001-5256.2014.07.012

Issue 7

Jul. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(7): 624-627

PDF( 1550 KB)

Diagnostic values of FibroScan and FibroTouch for liver fibrosis: a comparative analysis

DOI: 10.3969/j.issn.1001-5256.2014.07.012

Department of Hepatology, The First Hospital of Jilin University

Research funding:

Received Date: 2014-06-24
Published Date: 2014-07-20

Abstract

Abstract

Objective To compare the diagnostic values of FibroScan and FibroTouch for liver fibrosis. Methods A total of 962 patients who visited Department of Hepatology, The First Hospital of Jilin University from September 2013 to March 2014 were enrolled. FibroScan and FibroTouch were performed among these patients. Thirty- three cases underwent liver biopsy, and Aspartate aminotransferase- to-platelet ratio index (APRI) was calculated in 66 patients (chronic hepatitis B (CHB) : 53 cases; chronic hepatitis C (CHC) : 13 cases) .Spearman rank correlation test was used to analyze the correlation between the results measured by FibroScan and FibroTouch. The diagnostic values of FibroScan and FibroTouch for liver fibrosis were analyzed and compared by receiver operating characteristic (ROC) curve. Results The analysis of liver stiffness measured by FibroScan and FibroTouch among all patients showed that the correlation coefficient between FibroScan and FibroTouch was 0. 866 (P < 0. 05, n = 962) . FibroScan and FibroTouch were significantly correlated with APRI (r = 0. 58 and0. 63, P < 0. 05, n = 66) and pathological stage determined by liver biopsy (r = 0. 67 and 0. 74, P < 0. 05, n = 33) . Among patients with CHB, for the diagnosis of APRI ≥2 (liver cirrhosis) , the areas under the ROC curve (AUCs) of FibroScan and FibroTouch were 0. 761 vs0. 728 (P = 0. 61) ; among patients with CHC, for the diagnosis of APRI ≥1 (liver cirrhosis) , the AUCs of FibroScan and FibroTouch were0. 810 vs 0. 893 (P = 0. 38) . For pathological stages ≥S1, ≥S2, ≥S3, and ≥S4, the AUCs of FibroScan and FibroTouch were 0. 830 vs0. 889 (P = 0. 15) , 0. 841 vs 0. 835 (P = 0. 90) , 0. 888 vs 0. 920 (P = 0. 43) , and 0. 964 vs 0. 979 (P = 0. 45) , respectively. Conclusion FibroScan and FibroTouch have comparable diagnostic values for liver fibrosis. However, the number of cases undergoing liver biopsy in this study was relatively small, and investigation of more cases is needed to make further confirmation.
- liver cirrhosis,
- FibroScan,
- FibroTouch,
- diagnosis,
- ROC curve

FullText(HTML)

References(16)

References

[1] GANEM D, PRINCE AM.Hepatitis B virus infection-natural historhy and clinical consequences[J].N Engl J Med, 2013, 11 (3) :1118-1129.

[2]ZHUANG H.Progress in epidemiology of hepatitis B[J/CD].Chin J Front Med Sci:Electronic Version, 2009, 1 (2) :18-24. (in Chinese) 庄辉.乙型肝炎流行病学研究进展[J/CD].中国医学前沿杂志:电子版, 2009, 1 (2) :18-24.

[3]ALBELDAWI M, RUIZ-RODRIGUEZ E, CAREY WD.Hepatitis C virus:prevention, screening, and interpretation of assays[J].Cleve Clin J Med, 2010, 77 (9) :616-626.

[4]Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline for prevention and treatment of chronic hepatitis B (version 2010) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[5]WAI CT, GREENSON JK, FONTANA RJ, et al.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J].Hepatology, 2003, 38 (2) :518-526.

[6]LINDOR KD, GERSHWIN ME, POUPON R, et al.Primary biliary cirrhosis[J].Hepatology, 2009, 50 (1) :291-308.

[7]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for Management ofnon-alcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[8]GAO RT, ZHU CL.Challenge of noninvasive assessment of liver fibrosis-progress in Fibroscan[J].J Prac Hepatol, 2009, 12 (6) :467-469. (in Chinese) 高人焘, 朱传龙.肝纤维化无创性诊断的挑战-Fibroscan技术新进展[J].实用肝脏病杂志, 2009, 12 (6) :467-469.

[9]WEI GX, WANG ZP.Application of ratio index of aspartate aminotransferase and platelet ratio on liver fibrosis classification of patients with chronic hepatitis B[J/CD].Chin J Liver Dis:Electronic Edition, 2013, 5 (2) :50-52. (in Chinese) 隗功贤, 王志鹏.慢性乙型肝炎患者肝纤维化分级中AST/PLT比值指数的临床研究[J/CD].中国肝脏病杂志:电子版, 2013, 5 (2) :50-52.

[10]CAI W, XIE Q, ZHOU HJ, et al.Aspartate aminotransferase to platelet ration index as a non-invasive parameter for predivting liver fibrosis in chronic hepatitis B[J].J Diagn Concepts Pract, 2009, 8 (2) :147-151. (in Chinese) 蔡伟, 谢青, 周惠娟, 等.天冬氨酸转氨酶与血小板比值在预测慢性乙型肝炎肝纤维化中的作用[J].诊断学理论与实践, 2009, 8 (2) :147-151.

[11]AVIHINGSANON A, JITMITRAPARP S, TANGKIJVANICH P, et al.Advanced liver fibrosis by Transient Elastography, FIB-4 and APRI among Asian hepatitis C with and without HIV infection:role of vitamin D levels[J].J Gastroenterol Hepatol, 2014.[Epub ahead of print]

[12]WAHL K, ROSENBERG W, VASKE B, et al.Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis score compared to transient elastography[J].PLoS One, 2012, 7 (12) :e51906.

[13]FRIEDRICH-RUST M, ONG MF, MARTENS S, et al.Performance of transient elastography for the staging of liver fibrosis:a meta-analysis[J].Gastroenterology, 2008, 134 (4) :960-974.

[14]CHON YE, CHOI EH, SONG KJ, et al.Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B:a meta-analysis[J].PLoS One, 2012, 7 (9) :e44930.

[15]TALWALKAR JA, KURTZ DM, SCHOENLEBER SJ, et al.Ultrasound-based transient elastography for the detection of hepatic fibrosis:systematic review and meta-analysis[J].Clin Gastroenterol Hepatol, 2007, 5 (10) :1214-1220.

[16]STEBBING J, FAROUK L, PANOS G, et al.A meta-analysis of transient elastography for the detection of hepatic fibrosis[J].J Clin Gastroenterol, 2010, 44 (3) :214-219.

Relative Articles

[1]	Zhuoga RENZENG, Kangjie YANG, Yongliang LU, Zhixin WANG, Haijiu WANG. Research advances in neutrophil extracellular traps and liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(3): 639-643. doi: 10.12449/JCH240334
[2]	Mingqiang ZHU, Xing XIE, Qicheng LIAO, Xiao HE, Youming DING, Xiaohua WANG. Mechanism of cuproptosis and its role in liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(11): 2332-2337. doi: 10.12449/JCH241131
[3]	Guiqiang WANG. Application and prospect of cell therapy in clinical treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1001-1003. doi: 10.3969/j.issn.1001-5256.2023.05.001
[4]	Zhuoran WANG, Bing ZHU, Limei YU, Shaoli YOU. Role of stem cell-derived exosomes in treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 699-706. doi: 10.3969/j.issn.1001-5256.2023.03.034
[5]	Feiyan LI, Minggang WANG, Dewen MAO, Xiongbin GUI. Role of gasdermin D in the pathological progression of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 707-712. doi: 10.3969/j.issn.1001-5256.2023.03.035
[6]	Wenshang CHEN, Jijin ZHU, Shilai LI. Role of thymic stromal lymphopoietin in liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1175-1178. doi: 10.3969/j.issn.1001-5256.2022.05.042
[7]	Weiyu CHEN, Faming SHU, Han WANG, Yanggang CAO, Jin HU, Dewen MAO. Role of the cytochrome P450 family in metabolic-associated liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(9): 2182-2187. doi: 10.3969/j.issn.1001-5256.2022.09.045
[8]	Rui CHEN, Zhixin WANG, Haining FAN, Haijiu WANG. Research advances in the role of lymphocyte activation gene-3 in liver-related diseases[J]. Journal of Clinical Hepatology, 2021, 37(4): 977-981. doi: 10.3969/j.issn.1001-5256.2021.04.056
[9]	Lihui ZHANG, Minghao LIU, Wenxia ZHAO. Role of lipotoxicity in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 463-466. doi: 10.3969/j.issn.1001-5256.2021.02.045
[10]	Feiyu ZHANG, ADILA·Yakepu, Jinming ZHAO, Yanhang GAO. Mechanism of ferroptosis and its role in liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(6): 1454-1458. doi: 10.3969/j.issn.1001-5256.2021.06.049
[11]	XU LiJun, AN XiuQin, LI Yue, LIU JinChun. Research advances in the role of myeloid-derived suppressor cells in liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2851-2855. doi: 10.3969/j.issn.1001-5256.2020.12.045
[12]	XIAO WeiSong, LE YingYu, ZENG ShengLan, TAN XiaoBin, WU Cong, YA ChengYu, MAO DeWen. Role of pyroptosis in liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2847-2850. doi: 10.3969/j.issn.1001-5256.2020.12.044
[13]	Wang ShaSha, Hua Fang, Jiao YongGeng, Qin ErYun, Zhi YiXiao, Pang MengYuan, Xu HongQin, Chi XiuMei, Niu JunQi, Hua Rui. Serum level of ceruloplasmin in patients with different liver diseases in Jilin,China[J]. Journal of Clinical Hepatology, 2020, 36(9): 2025-2029. doi: 10.3969/j.issn.1001-5256.2020.09.023
[14]	Chen ShuRu, Chong YuTian, Li XinHua. Pathogenic mechanism and clinical diagnosis of hereditary abnormal copper metabolism[J]. Journal of Clinical Hepatology, 2019, 35(8): 1667-1672. doi: 10.3969/j.issn.1001-5256.2019.08.003
[15]	Yu PengFei, Wu Qiao, Duan ZhongPing, Chen Yu. Research advances in the mechanism of drug-induced liver injury due to paracetamol[J]. Journal of Clinical Hepatology, 2019, 35(9): 2108-2112. doi: 10.3969/j.issn.1001-5256.2019.09.050
[16]	Chen Xiang, Wen DiGuang, You Yu, Gong JianPing. Role and mechanism of ferroptosis in treatment of liver cancer with sorafenib[J]. Journal of Clinical Hepatology, 2019, 35(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2019.10.040
[17]	Bao SuXia, Zheng JianMing, Shi GuangFeng. Research progress in association between interleukin-23 and liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(2): 393-396. doi: 10.3969/j.issn.1001-5256.2016.02.044
[18]	Lu: XinPing, Wu Jing, Chen JingTao. Application of antibody preparation technology based on single B lymphocytes in liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(12): 2104-2109. doi: 10.3969/j.issn.1001-5256.2015.12.028
[19]	Huang LanYu, Xu LieMing. Relationship between liver diseases and autophagy[J]. Journal of Clinical Hepatology, 2014, 30(2): 186-188. doi: 10.3969/j.issn.1001-5256.2014.02.022
[20]	Liu GuoWang, Cao WuKui. Application of stem cells in liver disease treatment[J]. Journal of Clinical Hepatology, 2011, 27(9): 999-1002.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	郭新华，王佳慧，段雪琳，彭岳，赵铁建，郑洋，赵斌. 金属离子代谢：慢性肝病中医药防治新思路. 临床肝胆病杂志. 2024(07): 1498-1504 . 本站查看
2.	董昌君，张先林. 铜死亡在肝细胞癌发病机制中的研究进展. 中国普通外科杂志. 2024(07): 1172-1179 .
3.	刘诗卉，李冬冬，张宏坤，刘传苗，吴执竞，赵文. 细胞死亡在NAFLD发生发展中的研究进展. 齐齐哈尔医学院学报. 2024(16): 1578-1582 .
4.	朱明强，谢星，廖启成，何晓，丁佑铭，王小华. 铜死亡的发生机制及在肝脏疾病中的作用. 临床肝胆病杂志. 2024(11): 2332-2337 . 本站查看

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (6632) PDF downloads(877)

Diagnostic values of FibroScan and FibroTouch for liver fibrosis: a comparative analysis

DOI: 10.3969/j.issn.1001-5256.2014.07.012